GlassScriptPhysician profile
Tyler Copeland
NPI 1114400090
$2,545.27
in general payments reported to CMS, 2019-2025
37 companies · $595 in 2025
The $595 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $500 · 2023: $471 · 2024: $529 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $333.15 | 2021-2025 | |
| Lilly USA, LLC | $328.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.78 | 2021-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $212.72 | 2022-2025 | Rexulti, Nuedexta |
| Daiichi Sankyo INC. | $134.85 | 2022-2024 | Injectafer |
| Novo Nordisk INC | $120.75 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Mylan Specialty L.P. | $112.77 | 2022-2023 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $107.07 | 2021-2025 | Farxiga, Lokelma, Breztri |
| Radius Health, INC. | $105.99 | 2023-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $91.71 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.57 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $88.05 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $58.26 | 2022 | |
| Nestle Healthcare Nutrition INC. | $48.06 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.46 | 2025 | Caplyta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $37.06 | 2024-2025 | Gemtesa |
| Lundbeck LLC | $29.24 | 2025 | Rexulti |
| Amgen INC. | $27.16 | 2021-2022 | |
| Amarin Pharma, INC. | $25.82 | 2021-2022 | |
| Eisai INC. | $24.92 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.14 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.96 | 2025 | Voquezna |
| Ardelyx, INC. | $20.64 | 2025 | Ibsrela |
| Pfizer INC. | $19.23 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.03 | 2021 | |
| Inspire Medical Systems, INC. | $18.85 | 2024 | Inspire |
| Abbott Laboratories | $17.91 | 2025 | Freestyle Libre 3 |
| Vertex Pharmaceuticals Incorporated | $17.45 | 2025 | |
| Insulet Corporation | $17.13 | 2022 | |
| Antares Pharma, INC. | $15.23 | 2024 | Xyosted |
| Dexcom, INC. | $14.94 | 2024 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $14.67 | 2021 | |
| Seqirus USA INC | $14.56 | 2025 | Flucelvax, Fluad |
| Esperion Therapeutics, INC. | $13.71 | 2025 | Nexletol |
| Ultragenyx Pharmaceutical INC. | $13.43 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Copeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.